Skip to main content
Premium Trial:

Request an Annual Quote

Oncimmune Inks Deal With Accu Reference to Offer EarlyCDT-Lung Test

NEW YORK (GenomeWeb) – UK-based diagnostics firm Oncimmune said today that it has signed an agreement with US clinical laboratory Accu Reference for the firm to offer Oncimmune's EarlyCDT-Lung test to physicians.

The EarlyCDT-Lung test measures levels of seven autoantibodies in patient blood to aid in the early detection of lung cancer. Oncimmune markets the test both for detecting lung cancer before it can be picked up via imaging techniques like CT scans and for helping to evaluate whether nodules detected via imaging are likely malignant or benign.

Accu Reference, which serves physicians in 15 states, plans to offer the test as a complement to CT-based lung cancer screening.

Based on technology spun out of the University of Nottingham, Oncimmune launched the test the UK in 2009 and in the US in 2012. According to the company it has to date sold more than 125,000 tests. The company also has a CLIA lab in Kansas City, Missouri.

Financial and other terms of the agreement were not disclosed.